Clinical Trials Logo

Filter by:
NCT ID: NCT05461209 Withdrawn - Clinical trials for Relapsed/ Refractory Multiple Myeloma

A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma

MonumenTAL-5
Start date: October 20, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of talquetamab versus belantamab mafodotin in terms of overall response rate (ORR) or progression-free survival (PFS).

NCT ID: NCT05461053 Withdrawn - Cutaneous Abscess Clinical Trials

Conservative Management of Cutaneous Abscess

Start date: January 2025
Phase: Phase 4
Study type: Interventional

This is a single center non-blinded randomized trial of topical anesthetic cream to usual care (warm compresses and time) for superficial, non-perianal abscesses in children under 18 years of age. The primary outcome is time to spontaneous drainage. The secondary outcomes are return to emergency room/hospital/care provider and need for incision and drainage. Information on patient experience using standardized patient reported outcome measures for health-related quality of life will also be gathered. The findings of this study will provide more robust evidence of the benefit of this treatment including a potential reduction in cost and allow for more widespread dissemination.

NCT ID: NCT05460624 Withdrawn - Cognition Clinical Trials

Daily Egg Consumption and Cognitive Function in Older Adults

Start date: February 10, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to test the effects of provisioning twelve eggs weekly, incorporated into breakfast meals, on composite scores of executive functioning and memory using the CNSVS computerized test platform in older adults in a randomized study.

NCT ID: NCT05458232 Withdrawn - Sarcopenia Clinical Trials

Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults

Start date: January 20, 2023
Phase:
Study type: Observational

This study will be the first demonstration of the utility and feasibility of Phosphodiesterase Type 5 inhibitor as an effective pharmacological therapy for improving anabolic resistant states.

NCT ID: NCT05457530 Withdrawn - Obesity Clinical Trials

Doravirine and Weight Gain in Antiretroviral Naive

DAWN
Start date: August 1, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is determine whether different antiretroviral therapy (ART) changes the effects on body fat and predict the weight change in Black and Hispanic females.

NCT ID: NCT05448118 Withdrawn - Clinical trials for Substance Use Disorder

Virtual MOUD Treatment- Virtual POC Toxicology

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Care for Substance use disorders (SUD) such as Medication treatment of Opioid Use Disorder (MOUD) saves lives and is increasingly delivered virtually. Currently, 60% of VA outpatient addiction treatment occurs over video. However, toxicology testing, a major component of SUD care, currently requires in-person visits. A process for virtual point-of-care toxicology testing is needed. This research will develop a Virtual Point-of-Care Toxicology Testing Process for VA. This Pilot Trial will evaluate the feasibility, acceptability, and proximal effects of the process by evaluating provider and patient testing uptake, qualitative feedback, and health service use.

NCT ID: NCT05445882 Withdrawn - Clinical trials for Castration Resistant Prostate Cancer

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

Background: Prostate cancer does not trigger a strong immune response in the body. Hormone therapy, to reduce levels of testosterone in the body, can be helpful to treat some prostate cancers. However, castration-resistant prostate cancer (CRPC) keeps growing even when the testosterone is reduced to a very low level. Men with metastatic CRPC survive an average of only 3 years. More effective treatments are needed. Objective: To test whether an immunotherapy drug (N-803), alone or in combination with other drugs, can help treat CRPC. Eligibility: Males aged 18 or older with CRPC. Prior treatment with testosterone-lowering therapy is required. Design: Participants will be screened. They will have blood and urine tests. They will have a CT scan of the chest, abdomen, and pelvis. They will continue to receive hormone therapy for prostate cancer. Participants will come to the NIH clinic once a week for the first 4 weeks. Then they will come once every 2 weeks. Visits will last up to 8 hours. The study will continue up to 3 years. All participants will receive N-803 once every 2 weeks. The drug is injected just under the skin with a small needle. Some participants will receive N-803 plus another drug (brachyury vaccine). This drug is also injected under the skin with a small needle. Some participants will receive N-803 plus a different drug (bintrafusp alfa) once every 2 weeks. This drug is given through a tube attached to a needle placed in a vein in the arm. Some participants may receive all 3 drugs. Participants will have imaging scans every 12 weeks.

NCT ID: NCT05441930 Withdrawn - Cataract Clinical Trials

A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery

Start date: June 23, 2023
Phase: Phase 1
Study type: Interventional

Open label controlled interventional study in eyes in up to 12 subjects (24 eyes) scheduled for uncomplicated bilateral cataract surgery on separate days.

NCT ID: NCT05440721 Withdrawn - Tobacco Dependence Clinical Trials

Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification

Start date: October 25, 2018
Phase: N/A
Study type: Interventional

This study is evaluating the efficacy of Treatment A for short-term smoking cessation through a blinded randomized controlled trial (RCT) vs.Treatment B.

NCT ID: NCT05436808 Withdrawn - Breast Cancer Clinical Trials

Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer

Start date: July 15, 2022
Phase: Early Phase 1
Study type: Interventional

The standard treatment for breast cancer when cancer cells were found near or within the margins of the tissue that is removed during breast surgery, is radiation of the entire chest wall. This may be considered overtreatment since the only reason for doing so is that cancer cells were near or in the margins of the breast tissue that was removed. In this study, the amount of radiation treatment will be limited to the area where the remaining cancer cells were found after surgery. The purpose of this study is to find out if partial chest wall radiation therapy is as good as whole chest wall radiation therapy in reducing the risk of breast cancer cancer coming back.